Interventions to Slow Aging in Humans: Are We Ready?

Valter D. Longo(University of Southern California), Adam Antebi(Max Planck Institute for Biology of Ageing), Andrzej Bartke(Southern Illinois University School of Medicine), Nir Barzilai(Albert Einstein College of Medicine), Holly M. Brown‐Borg(University of North Dakota), Calogero Caruso(University of Palermo), Tyler J. Curiel(The University of Texas at San Antonio Health Science Center), Rafael de Cabo(National Institute on Aging), Claudio Franceschi(University of Bologna), David Gems(University College London), Donald K. Ingram(Pennington Biomedical Research Center), Thomas E. Johnson(University of Colorado Boulder), Brian K. Kennedy(Buck Institute for Research on Aging), Cynthia Kenyon(Genentech), Samuel Klein(Washington University in St. Louis), John J. Kopchick(Ohio University), Günter Lepperdinger(Universität Innsbruck), Frank Madeo(University of Graz), Mario G. Mirisola(University of Palermo), James R. Mitchell(Harvard University), Giuseppe Passarino(University of Calabria), K. Lenhard Rudolph(Leibniz Institute on Aging - Fritz Lipmann Institute (FLI)), John M. Sedivy(Brown University), Gerald S. Shadel(Yale University), David Sinclair(Harvard University), Stephen R. Spindler(University of California, Riverside), Yousin Suh(Albert Einstein College of Medicine), Jan Vijg(Albert Einstein College of Medicine), Manlio Vinciguerra(The Royal Free Hospital), Luigi Fontana(Washington University in St. Louis)
Aging Cell
April 22, 2015
Cited by 596Open Access
Full Text

Abstract

The workshop entitled 'Interventions to Slow Aging in Humans: Are We Ready?' was held in Erice, Italy, on October 8-13, 2013, to bring together leading experts in the biology and genetics of aging and obtain a consensus related to the discovery and development of safe interventions to slow aging and increase healthy lifespan in humans. There was consensus that there is sufficient evidence that aging interventions will delay and prevent disease onset for many chronic conditions of adult and old age. Essential pathways have been identified, and behavioral, dietary, and pharmacologic approaches have emerged. Although many gene targets and drugs were discussed and there was not complete consensus about all interventions, the participants selected a subset of the most promising strategies that could be tested in humans for their effects on healthspan. These were: (i) dietary interventions mimicking chronic dietary restriction (periodic fasting mimicking diets, protein restriction, etc.); (ii) drugs that inhibit the growth hormone/IGF-I axis; (iii) drugs that inhibit the mTOR-S6K pathway; or (iv) drugs that activate AMPK or specific sirtuins. These choices were based in part on consistent evidence for the pro-longevity effects and ability of these interventions to prevent or delay multiple age-related diseases and improve healthspan in simple model organisms and rodents and their potential to be safe and effective in extending human healthspan. The authors of this manuscript were speakers and discussants invited to the workshop. The following summary highlights the major points addressed and the conclusions of the meeting.


Related Papers

No related papers found

Powered by citation graph analysis